PMID: 9522115Apr 2, 1998Paper

Risperidone versus haloperidol: II. Cost-effectiveness

Clinical Therapeutics
A DaviesI Schweitzer


Australia and Canada are currently the only Western nations with government guidelines for analyzing the cost-effectiveness of drugs. We used guidelines issued by the Australian Pharmaceutical Benefits Advisory Committee to construct a model for comparing the cost-effectiveness of risperidone and haloperidol over a 2-year period in patients with chronic schizophrenia. Use of clozapine was also included in the analysis as an alternative treatment given to patients who proved unresponsive to therapy with haloperidol or risperidone. Results are expressed in Australian dollars. Cost-effectiveness was determined by using decision-analytic modeling to compare clinical outcomes and costs. The analytic model contained a decision tree for each of the compared agents that tracked the distribution of patients between treatment outcome pathways (i.e., scenarios). Distributions were based on probabilities derived from our meta-analysis results reported elsewhere and from other sources. Each scenario had an associated monetary cost that included all significant direct costs (i.e., hospital costs; outpatient costs; and the cost of drugs, the services of health care professionals, and government-subsidized hostel accommodation). The cost for a...Continue Reading


Jan 1, 1991·Schizophrenia Bulletin·G Andrews
Jun 1, 1985·Archives of General Psychiatry·G AndrewsD Silove
Jan 1, 1981·Schizophrenia Bulletin·E F Torrey
Jan 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·L M Davies, M F Drummond
Jan 1, 1996·European Archives of Psychiatry and Clinical Neuroscience·H J Möller
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Aug 6, 1993·PharmacoEconomics·M DrummondH Sintonen

❮ Previous
Next ❯


Mar 11, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Karina HansenMondher Toumi
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Feb 20, 2003·Schizophrenia Research·Teresa J HudsonCarol R Thrush
Aug 2, 2003·Schizophrenia Research·Rahul GangulyBradley C Martin
Sep 17, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·L Hosák, R Bahbouh
Mar 12, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Nadeem H BhanjiHoward C Margolese
Jan 22, 2003·The Australian and New Zealand Journal of Psychiatry·Amanda L NeilVaughan J Carr
Jul 19, 2001·International Clinical Psychopharmacology·S KasperUNKNOWN RODOS Investigator Group
Jan 22, 2005·The Australian and New Zealand Journal of Psychiatry·Anne MagnusTheo Vos
Jun 1, 2006·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Ruth Williams, Darrel Doessel
Nov 14, 2007·International Journal of Clinical Practice·M ObradovicM Kos
Apr 12, 2011·Journal of Pain and Symptom Management·Paul HowardAndrew Wilcock
May 24, 2007·Journal of Evaluation in Clinical Practice·Mark Bounthavong, Mark P Okamoto
Apr 10, 2003·The Psychiatric Clinics of North America·Robin Emsley, Piet Oosthuizen
Jul 14, 2000·Current Medical Research and Opinion·B Green
Mar 16, 2001·Expert Opinion on Pharmacotherapy·D A Revicki
Mar 16, 2001·Expert Opinion on Pharmacotherapy·B C Lund, P J Perry
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Hans-Jürgen Möller
Jan 20, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Bertalan NémethBalázs Nagy
Sep 24, 2004·Pharmacoepidemiology and Drug Safety·A LealG Remington
Feb 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Reinhold Kilian, Thomas Becker
Jul 5, 2011·Expert Review of Neurotherapeutics·Maurizio PompiliPaolo Girardi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here